

PE anti-human EGFR

Catalog # / Size: 2364515 / 25 tests
2364520 / 100 tests

Clone: AY13

Isotype: Mouse IgG1, κ


Immunogen: Non-small cell lung cancer (NSCLC) cell line NCI-H322

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

Concentration: Lot-specific



Human cervical cancer cell line HELA was stained with EGFR (clone AY13) PE (filled histogram) or mouse IgG1, κ PE isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. **Test size products are transitioning from 20 microL to 5 microL per test.** Please check your vial or your CoA to find the suggested use of this reagent per million cells in 100 microL staining volume or per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application References:

1. Yamaguchi M, *et al.* 2009. The 15th Annual Meeting Japan Society of Gene Therapy. p1056. Abstract 92.
2. Wang Y, *et al.* 2014. *Biomaterials*. 35:4297. [PubMed](#)

Description: Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and member of the protein kinase superfamily that regulates cell growth and differentiation. EGFR binds EGF, TGF- α , amphiregulin, β cellulin, heparin-binding EGF-like growth factor, GP30, and vaccinia virus growth factor - all members of the EGF family. Ligand binding induces EGFR dimerization and autophosphorylation, initiating the MAPK, Akt, and JNK signaling pathways. EGFR is expressed by epithelial and endothelial cells and is frequently expressed by epithelial carcinomas.

Antigen References:

1. da Cunha Santos G, *et al.* 2011. *Annu. Rev. Pathol.* 6:49.
2. Gusterson BA and Hunter KD. 2009. *Lancet Oncol.* 10:522.
3. Mano M and Humblet Y. 2008. *Nat. Clin. Pract. Oncol.* 5:415.
4. Pao W and Chm